Aveo Oncology ($AVEO), battered by a long series of clinical setbacks, says it has found a potential path to success with tivozanib, a cancer treatment that has failed in three trials. Looking over data from a Phase II study in colorectal cancer, the company noted that patients with low levels of the protein NRP-1 showed an improvement in progression-free survival on tivozanib compared to placebo. It should of course be noted that that same study was terminated early when Aveo revealed that tivozanib was unlikely to meet its primary endpoint, eventually leading ex-partner Astellas to abandon the program altogether. Still, the company's shares jumped nearly 40% on the latest subpopulation analysis. More